Literature DB >> 29236146

[Atherothrombosis : Novel therapeutic strategies].

O Soehnlein1,2,3.   

Abstract

Despite intensive scientific research over the past decades, atherosclerosis and atherothrombosis are the leading cause of mortality worldwide. During the recent past it has become clear that atherosclerosis is not merely a lipid-driven disease but a multifactorial process involving chronic inflammation of large arteries. This review article briefly outlines the mechanistic nature of atherosclerosis, presents a synopsis of the current state of the art treatment strategies and finally outlines several therapeutic options, which are in clinical and experimental testing.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular diseases; Hyperlipidemia; Inflammation; Platelet inhibition

Mesh:

Substances:

Year:  2018        PMID: 29236146     DOI: 10.1007/s00059-017-4659-x

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  63 in total

1.  Ticagrelor--is there need for a new player in the antiplatelet-therapy field?

Authors:  Albert Schömig
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

2.  Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy.

Authors:  Christopher J Franzese; Kevin P Bliden; Martin G Gesheff; Shachi Pandya; Kirk E Guyer; Anand Singla; Udaya S Tantry; Peter P Toth; Paul A Gurbel
Journal:  Am J Cardiol       Date:  2015-02-12       Impact factor: 2.778

3.  Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  John J P Kastelein; Joost Besseling; Sukrut Shah; Jean Bergeron; Gisle Langslet; G Kees Hovingh; Naab Al-Saady; Michiel Koeijvoets; John Hunter; Amy O Johnson-Levonas; Jennifer Fable; Aditi Sapre; Yale Mitchel
Journal:  Lancet       Date:  2015-03-03       Impact factor: 79.321

Review 4.  Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies.

Authors:  Carlos Silvestre-Roig; Menno P de Winther; Christian Weber; Mat J Daemen; Esther Lutgens; Oliver Soehnlein
Journal:  Circ Res       Date:  2014-01-03       Impact factor: 17.367

5.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Authors:  Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Reda Ibrahim; Jacques Lespérance; Therese M Heinonen; Simon Kouz; Colin Berry; Russell Basser; Marc-André Lavoie; Marie-Claude Guertin; Josep Rodés-Cabau
Journal:  JAMA       Date:  2007-03-26       Impact factor: 56.272

6.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

7.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245

8.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

Authors:  Michelle L O'Donoghue; Eugene Braunwald; Harvey D White; Dylan P Steen; Mary Ann Lukas; Elizabeth Tarka; P Gabriel Steg; Judith S Hochman; Christoph Bode; Aldo P Maggioni; KyungAh Im; Jennifer B Shannon; Richard Y Davies; Sabina A Murphy; Sharon E Crugnale; Stephen D Wiviott; Marc P Bonaca; David F Watson; W Douglas Weaver; Patrick W Serruys; Christopher P Cannon; Dylan L Steen
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

9.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors:  Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal:  Lancet       Date:  2012-11-02       Impact factor: 79.321

Review 10.  Dual pathway therapy in acute coronary syndrome.

Authors:  Peter Stachon; Ingo Ahrens; Christoph Bode; Andreas Zirlik
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.